109 related articles for article (PubMed ID: 21366826)
1. Tissue distribution of dexamethasone in feline ocular structures following single topical application of dexamethasone as an ointment or suspension.
Bessonova J; Meyer-Lindenberg A; Bäumer W; Kietzmann M
Vet Ophthalmol; 2011 Mar; 14(2):109-13. PubMed ID: 21366826
[TBL] [Abstract][Full Text] [Related]
2. Tissue distribution of dexamethasone in canine ocular compartments following topical application of dexamethasone-21-isonicotinate and oxytetracycline HCl.
Kaiser T; Werner A; Bäumer W; Kietzmann M
Vet Ophthalmol; 2008; 11(5):335-9. PubMed ID: 19046294
[TBL] [Abstract][Full Text] [Related]
3. AL-2512, a novel corticosteroid: preclinical assessment of anti-inflammatory and ocular hypertensive effects.
Bhattacherjee P; Mukhopadhyay P; Paterson CA; Graff G; Gamache DA; Yanni JM
J Ocul Pharmacol Ther; 2003 Aug; 19(4):353-60. PubMed ID: 12964959
[TBL] [Abstract][Full Text] [Related]
4. Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops.
Loftsson T; Hreinsdóttir D; Stefánsson E
J Pharm Pharmacol; 2007 May; 59(5):629-35. PubMed ID: 17524227
[TBL] [Abstract][Full Text] [Related]
5. Ocular distribution, bactericidal activity and settling characteristics of TobraDex ST ophthalmic suspension compared with TobraDex ophthalmic suspension.
Scoper SV; Kabat AG; Owen GR; Stroman DW; Kabra BP; Faulkner R; Kulshreshtha AK; Rusk C; Bell B; Jamison T; Bernal-Perez LF; Brooks AC; Nguyen VA
Adv Ther; 2008 Feb; 25(2):77-88. PubMed ID: 18309465
[TBL] [Abstract][Full Text] [Related]
6. PLGA-PEG-PLGA hydrogel for ocular drug delivery of dexamethasone acetate.
Gao Y; Sun Y; Ren F; Gao S
Drug Dev Ind Pharm; 2010 Oct; 36(10):1131-8. PubMed ID: 20334543
[TBL] [Abstract][Full Text] [Related]
7. Systemic dexamethasone concentration in horses after continued topical treatment with an ophthalmic preparation of dexamethasone.
Spiess BM; Nyikos S; Stummer E; Sahin A; Naegeli H
Am J Vet Res; 1999 May; 60(5):571-6. PubMed ID: 10328426
[TBL] [Abstract][Full Text] [Related]
8. Albumin microsphere as a drug delivery system for dexamethasone: pharmacokinetics in sheep, residue amount in cows and distribution in rats.
Dilova V; Konakchieva R; Kanchev L; Dilov P
Boll Chim Farm; 1999 Oct; 138(9):465-70. PubMed ID: 10682405
[TBL] [Abstract][Full Text] [Related]
9. Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye.
Sigurdsson HH; Konráethsdóttir F; Loftsson T; Stefánsson E
Acta Ophthalmol Scand; 2007 Sep; 85(6):598-602. PubMed ID: 17645424
[TBL] [Abstract][Full Text] [Related]
10. Dexamethasone eye drops containing γ-cyclodextrin-based nanogels.
Moya-Ortega MD; Alves TF; Alvarez-Lorenzo C; Concheiro A; Stefánsson E; Thorsteinsdóttir M; Loftsson T
Int J Pharm; 2013 Jan; 441(1-2):507-15. PubMed ID: 23149258
[TBL] [Abstract][Full Text] [Related]
11. New quinolone/steroid combination for topical treatment of acute otitis: early- and late-phase study results.
Conroy PJ
Ear Nose Throat J; 2003 Aug; 82(8 Suppl 2):2-4. PubMed ID: 12974049
[No Abstract] [Full Text] [Related]
12. [The particle size of dexamethasone incorporated in ointments and its relation to the penetration of emulsion ointments into the horny layer of the skin in vivo].
Kleine-Natrop HE
Rev Med Chir Soc Med Nat Iasi; 1976; 80(3):425-31. PubMed ID: 1024238
[No Abstract] [Full Text] [Related]
13. Effects of dermal dexamethasone application on ACTH and both basal and ACTH-stimulated cortisol concentration in normal horses.
Abraham G; Allersmeier M; Gottschalk J; Schusser GF; Hoppen HO; Ungemach FR
J Vet Pharmacol Ther; 2009 Aug; 32(4):379-87. PubMed ID: 19614843
[TBL] [Abstract][Full Text] [Related]
14. Distribution of clobetasone in rabbit eye tissues after topical application.
Rink H; Connors B; Wegener A; Umlauf A; Hockwin O
Lens Eye Toxic Res; 1989; 6(1-2):353-63. PubMed ID: 2488027
[TBL] [Abstract][Full Text] [Related]
15. In Vitro/In Vivo Evaluation of Dexamethasone--PAMAM Dendrimer Complexes for Retinal Drug Delivery.
Yavuz B; Pehlivan SB; Vural İ; Ünlü N
J Pharm Sci; 2015 Nov; 104(11):3814-3823. PubMed ID: 26227825
[TBL] [Abstract][Full Text] [Related]
16. Ocular Physiologically Based Pharmacokinetic Modeling for Ointment Formulations.
Le Merdy M; Spires J; Lukacova V; Tan ML; Babiskin A; Xu X; Zhao L; Bolger MB
Pharm Res; 2020 Nov; 37(12):245. PubMed ID: 33215336
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of a ricinoleic acid poloxamer gel system for transdermal eyelid delivery.
Boddu SH; Gupta H; Bonam SP
Int J Pharm; 2014 Aug; 470(1-2):158-61. PubMed ID: 24813783
[TBL] [Abstract][Full Text] [Related]
18. Sustained release ophthalmic dexamethasone: In vitro in vivo correlations derived from the PK-Eye.
Awwad S; Day RM; Khaw PT; Brocchini S; Fadda HM
Int J Pharm; 2017 Apr; 522(1-2):119-127. PubMed ID: 28232270
[TBL] [Abstract][Full Text] [Related]
19. Topical ciprofloxacin/dexamethasone otic suspension is superior to ofloxacin otic solution in the treatment of granulation tissue in children with acute otitis media with otorrhea through tympanostomy tubes.
Roland PS; Dohar JE; Lanier BJ; Hekkenburg R; Lane EM; Conroy PJ; Wall GM; Dupre SJ; Potts SL;
Otolaryngol Head Neck Surg; 2004 Jun; 130(6):736-41. PubMed ID: 15195060
[TBL] [Abstract][Full Text] [Related]
20. Pooled analysis of two clinical trials comparing the clinical outcomes of topical ciprofloxacin/dexamethasone otic suspension and polymyxin B/neomycin/hydrocortisone otic suspension for the treatment of acute otitis externa in adults and children.
Rahman A; Rizwan S; Waycaster C; Wall GM
Clin Ther; 2007 Sep; 29(9):1950-6. PubMed ID: 18035194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
